Nyxoah SA has announced its financial and operating results for the third quarter of 2026, showcasing a robust performance that highlights the company's growth in the medical technology sector. The report, filed on November 5, 2026, indicates that Nyxoah experienced a substantial increase in U.S. revenue, which is pivotal for the company's future growth and market positioning.

Nyxoah SA, incorporated in Belgium, operates within the Surgical & Medical Instruments & Apparatus industry, as classified under SIC 3841. The company trades on the Nasdaq under the ticker symbol NYXH. With a focus on innovative solutions for obstructive sleep apnea (OSA), Nyxoah has made significant strides since its inception, particularly following its FDA approval in August 2025.

The latest filing reveals that Nyxoah's global net revenue for the third quarter reached €9.2 million, marking a 19% increase compared to the previous quarter. Notably, U.S. net revenue surged by 29% sequentially, reaching €6.7 million. This growth reflects the positive reception of Nyxoah's Genio system, which offers a novel treatment option for OSA.

In the filing, Nyxoah stated, "We delivered 29% sequential U.S. revenue growth in the third quarter, an acceleration from 22% in the second quarter. Momentum is building as physicians and centers gain experience with Genio." This statement underscores the company's confidence in its product and its strategy to expand its market share.

Nyxoah's growth trajectory is further supported by the training of 80 new surgeons during the quarter, bringing the total to 342 trained professionals. Additionally, the company activated 53 new accounts, resulting in a total of 233 active Genio accounts. These developments indicate a growing acceptance of Nyxoah's technology among healthcare providers.

Moreover, Nyxoah has submitted a premarket approval (PMA) supplement to the FDA to expand the Genio system's U.S. indication to include patients with Complete Concentric Collapse (CCC), a condition that currently has limited treatment options. This strategic move is expected to enhance the company's market presence and address a significant patient need.

Nyxoah's financial report also highlighted the company's gross profit for the quarter, which stood at €5.8 million, resulting in a gross margin of 63.1%. This improvement from a gross margin of 60.5% in the same period last year reflects operational efficiencies as production volumes increase.

Despite the positive revenue growth, Nyxoah reported an operating loss of €21.9 million for the quarter, although this was an improvement from a loss of €24.4 million in Q3 2025. The reduction in operating loss is attributed to higher gross profits and a decrease in research and development expenses, as the company shifts its focus toward commercial execution.

As of September 30, 2026, Nyxoah's cash, cash equivalents, and financial assets totaled €77.1 million, a decrease from €97.8 million at the end of the previous quarter. This liquidity position will be crucial as the company continues to invest in growth and innovation.

Looking ahead, Nyxoah expects its global net revenue for the full year 2026 to fall between €33 million and €35 million, with a gross margin projected between 60% and 62%. These projections reflect the company's optimism about its ongoing commercialization efforts and the increasing demand for its products.

Nyxoah's management will host a conference call to discuss these financial results on November 5, 2026, at 10:30 pm CET / 4:30 pm ET. The call will be accessible via the company's Investor Relations page, providing an opportunity for stakeholders to gain further insights into Nyxoah's strategies and future plans.

As Nyxoah continues to innovate and expand its market presence, its performance may set a benchmark for others in the surgical and medical instruments industry. The company's commitment to addressing the needs of OSA patients through cutting-edge technology positions it as a key player in the evolving healthcare landscape.